Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines
<p>Abstract</p> <p>Background</p> <p>Imatinib mesylate is currently the drug of choice to treat chronic myeloid leukemia. However, patient resistance and cytotoxicity make secondary lines of treatment, such as omacetaxine mepesuccinate, a necessity. Given that drug cyto...
Main Authors: | Kulkarni Hemant, Göring Harald H H, Diego Vincent, Cole Shelley, Walder Ken R, Collier Greg R, Blangero John, Carless Melanie A |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-08-01
|
Series: | BMC Medical Genomics |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1755-8794/5/37 |
Similar Items
-
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
by: Chen Y, et al.
Published: (2014-01-01) -
Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01) -
Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01) -
Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01) -
The teratogenic effects of imatinib mesylate on rat fetuses
by: M.M. El Gendy, et al.
Published: (2015-01-01)